



FOR IMMEDIATE RELEASE

**Tanvex BioPharma, Inc. has applied for primary listing on the Taiwan Stock Exchange**

Irvine, CA, November 30, 2016

Tanvex BioPharma Inc. ("Tanvex", stock code 6541) has applied for primary listing on the Taiwan Stock Exchange on November 30th, 2016. The company is the ninth foreign company who filed an IPO application to the Taiwan Stock Exchange this year.

Tanvex is registered in the Cayman Islands with its main operations located in Taiwan and America . Its core business is focusing on research and development, manufacturing, and marketing biosimilars products and new drugs.

For the first three quarters in 2016, Tanvex's consolidated revenue is NT\$0, net loss after tax attributable to owner is NTD\$ 779 million and net loss after tax per share is NTD\$ 4.17.

###